"A sensitive in vivo method for detecting molecular targets associated with specific cancer phenotypes could have tremendous value in cancer diagnosis and beyond."
Manhattan Scientifics, Inc. announced today that its Senior Scientific unit, developing a platform for the early detection of cancer and other human diseases, has established a Research Collaboration with The University of Michigan Medical School. The collaboration’s goal is to demonstrate the applicability of the company’s magnetic relaxometry technology for diagnosing and staging breast cancers.
“We are eager to begin research with the MRX platform,” said Brian D. Ross, Ph.D., Professor of Radiology and Biological Chemistry at the University of Michigan Medical School. “A sensitive in vivo method for detecting molecular targets associated with specific cancer phenotypes could have tremendous value in cancer diagnosis and beyond.”
“Mid-2015 we announced our intention to expand our collaborations. Dr. Ross and the team at the University of Michigan will add significant depth to our breast cancer program,” said Bob Proulx, President and COO of Senior Scientific. “The testing and data we obtain will be important as we prepare to bring the MRX technology to the FDA for diagnostic use.”
On December 14, 2015, the company announced a renewal and expansion of its relationship with the MD Anderson Cancer Center. That program, together with the work to be undertaken at the University of Michigan, will significantly contribute to the company’s efforts to progress to first in human testing of the technology.
Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.